[G26-17] Teplizumab (type 1 diabetes mellitus, stage 2, >= 8 years) – Second addendum to Project A26-11
Last updated 06.08.2026
Project no.:
G26-17
Commission:
Commission awarded on 23.06.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Topic:
Digestion, metabolism and hormones
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG submits an addendum. The G-BA decides on the number of patients in the SHI target population.
DOI:
https://doi.org/10.60584/G26-17
| Project no. | Title | Status |
|---|---|---|
| A26-11 | Teplizumab (type 1 diabetes mellitus, >= 8 years) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
06-08-2026 A G-BA decision was published.
G-BA documents on this decision